This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Myocarditis Treatment Trial

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
University of Utah Identifier:
First received: October 27, 1999
Last updated: November 25, 2013
Last verified: November 2013
To determine whether immunosuppressive treatment improved cardiac function in patients with biopsy-proven myocarditis.

Condition Intervention Phase
Cardiovascular Diseases Heart Diseases Myocarditis Drug: cyclosporine Drug: prednisone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Utah:

Study Start Date: July 1986
Study Completion Date: March 1994
Detailed Description:


Heart failure due to myocarditis can be a devastating illness. At the same time, immunosuppressive therapy is associated with considerable risks of untoward side effects. Clinicians did not know whether, under what circumstances, or in what form, this hazardous treatment should be used in such critically ill patients. In addition, if immunosuppressive therapy was of benefit, then endomyocardial biopsy in patients suspected of having myocarditis was a justified procedure. The trial also provided information concerning the side effects of immuno-suppressive therapy in such patients.


Patients were randomized into two treatment arms consisting of conventional therapy alone for congestive heart failure or combined with a twenty-four week regimen of immunosuppressive therapy. Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine. The primary outcome measure was a change in the left ventricular ejection fraction at twenty-eight weeks. Secondary endpoints included survival, failures of therapy, requirements for conventional therapy, assessments of symptoms, myocardial histology, and arrhythmias.

The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000524

Sponsors and Collaborators
University of Utah
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: Jay Mason University of Utah
  More Information

Publications: Identifier: NCT00000524     History of Changes
Other Study ID Numbers: 43
R01HL034744-04 ( U.S. NIH Grant/Contract )
Study First Received: October 27, 1999
Last Updated: November 25, 2013

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on August 22, 2017